Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration an… Read more
Metagenomi, Inc. Common Stock (MGX) - Net Assets
Latest net assets as of September 2025: $178.45 Million USD
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has net assets worth $178.45 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($247.94 Million) and total liabilities ($69.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $178.45 Million |
| % of Total Assets | 71.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Metagenomi, Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Metagenomi, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Metagenomi, Inc. Common Stock (2021–2024)
The table below shows the annual net assets of Metagenomi, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $234.86 Million | +9.15% |
| 2023-09-30 | $215.17 Million | +389.10% |
| 2022-09-30 | $-74.43 Million | -128.70% |
| 2021-09-30 | $-32.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Metagenomi, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18990600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $709.00K | 0.30% |
| Other Components | $457.15 Million | 194.65% |
| Total Equity | $234.86 Million | 100.00% |
Metagenomi, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tile Shop Holdings Inc
NASDAQ:TTSH
|
$39.79 Million |
|
Bon Fame Co Ltd
TWO:8433
|
$39.80 Million |
|
SBF AG
F:CY1K
|
$39.81 Million |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
$39.81 Million |
|
Rectron Ltd
TW:2302
|
$39.77 Million |
|
Aker Horizons ASA
PINK:AKHOF
|
$39.77 Million |
|
Arovella Therapeutics Ltd
AU:ALA
|
$39.76 Million |
|
Gowa Makassar Tourism Develop
JK:GMTD
|
$39.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Metagenomi, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 215,174,000 to 234,857,000, a change of 19,683,000 (9.1%).
- Net loss of 78,058,000 reduced equity.
- New share issuances of 84,013,000 increased equity.
- Other comprehensive income decreased equity by 8,625,000.
- Other factors increased equity by 22,353,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-78.06 Million | -33.24% |
| Share Issuances | $84.01 Million | +35.77% |
| Other Comprehensive Income | $-8.62 Million | -3.67% |
| Other Changes | $22.35 Million | +9.52% |
| Total Change | $- | 9.15% |
Book Value vs Market Value Analysis
This analysis compares Metagenomi, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $-5.49 | $1.46 | x |
| 2022-09-30 | $-1.99 | $1.46 | x |
| 2023-09-30 | $5.74 | $1.46 | x |
| 2024-09-30 | $6.28 | $1.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Metagenomi, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -149.26%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.38x
- Recent ROE (-33.24%) is below the historical average (-16.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -8823.87% | 0.00x | 0.00x | $-18.19 Million |
| 2022 | 0.00% | -253.45% | 0.04x | 0.00x | $-36.15 Million |
| 2023 | -31.72% | -152.50% | 0.12x | 1.70x | $-89.77 Million |
| 2024 | -33.24% | -149.26% | 0.16x | 1.38x | $-101.54 Million |
Industry Comparison
This section compares Metagenomi, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $178.45 Million | 0.00% | 0.39x | $39.79 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |